⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Rigel Pharmaceuticals, Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Rigel Pharmaceuticals, Inc.
↗South San Francisco, USA
Rigel Pharmaceuticals is a commercial-stage biotechnology company focused on discovering, developing, and providing novel therapies for patients with hematologic disorders and cancer. The company leverages its expertise in signaling pathways to develop small-molecule drugs and has expanded its portfolio through strategic in-licensing of commercial assets.
Rigel's commercial portfolio includes TAVALISSE® (fostamatinib), GAVRETO® (pralsetinib), and REZLIDHIA® (olutasidenib). The company is actively advancing its clinical pipeline, including R289, a dual IRAK1/4 inhibitor, and has recently secured global rights to VEPPANU™ (vepdegestrant), a PROTAC therapy for breast cancer.
CLASSIFICATION
SIZE & FINANCIALS
Employees:201-500
Revenue:$275M-$290M
Founded:1996
Ownership:public
Status:operating
FUNDING
Investors:Sutter Hill Ventures, TVM Capital, Alta Partners
STOCK
Exchange:NASDAQ
Ticker:RIGL
Market Cap:$0.22B
PIPELINE
Stage:Phase 1
Lead Drug Stage:Commercial
Modalities:Small molecule, PROTAC
Trial Phases:Phase 1: 1
FDA Approvals:3
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Eli Lilly (Development collaboration), Arvinas and Pfizer (Licensing of VEPPANU), MD Anderson Cancer Center (Evaluation of olutasidenib), CONNECT (Evaluation of olutasidenib)
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Raul Rodriguez - President and CEO
Scientific Founders:Donald G. Payan, James M. Gower, Ronald B. Lewis, Gary L. Lyons
Board Members:Michael P. Miller, Mark W. Frohlich, Gregg LaPointe, Walter Moos
LINKS
Website:rigel.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Rigel Pharmaceuticals, Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.